OSTEOSARCOMA RECURRENT
Clinical trials for OSTEOSARCOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OSTEOSARCOMA RECURRENT trials appear
Sign up with your email to follow new studies for OSTEOSARCOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo offers hope for kids with relapsed cancers
Disease control Recruiting nowThis study tests two oral drugs, eflornithine (DFMO) and AMXT 1501, in children and young adults up to age 26 with certain cancers that have come back or not responded to treatment. The cancers include neuroblastoma, brain tumors, and sarcomas. The goal is to find a safe dose and…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Promising combo targets Hard-to-Treat childhood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental combo aims to tackle tough bone cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called tegavivint combined with the chemotherapy gemcitabine in 24 people whose osteosarcoma (a type of bone cancer) has returned or not responded to prior treatment. The main goal is to find the safest dose of tegavivint when given with ge…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a drug keep sarcoma from returning? new trial hopes so
Disease control Recruiting nowThis study tests whether DFMO, a drug taken by mouth, can help prevent cancer from coming back in people with relapsed Ewing sarcoma or osteosarcoma who have finished all planned treatment and show no signs of disease. The trial will enroll 15 participants under age 40. The main …
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC